
Telix Pharmaceuticals revenue rises 19% to US$245M
- Telix Pharmaceuticals reported group revenue of US$245 million for the third quarter of 2026, marking a 19% increase from the prior corresponding period.
- Strong commercial demand for precision medicine imaging products drove quarterly revenue higher.
- The company reaffirmed its full-year 2026 revenue guidance to exceed US$1 billion.
Telix Pharmaceuticals (ASX:TLX) generated US$245 million in group revenue during the third quarter of 2026, up 19% in the prior-year period.
The quarterly revenue growth was primarily led by a 30% increase in precision medicine revenue to US$201 million, which offset a 6% decline in manufacturing solutions revenue.
The company stated that the transaction with Isotope Technologies Munich SE is expected to position the platform with one of the industry's broadest therapeutics pipelines.
In addition, research and development expenditure guidance for the full 2026 year was revised to a range of US$240 million to US$260 million.
Following the announcement, the Telix Pharmaceuticals share price was unchanged at $15.76.
The company secured regulatory approval from the U.S. Food and Drug Administration for its Pixclara glioma imaging agent in September.
Telix Pharmaceuticals also completed patient enrolment for its Phase 3 pre-biopsy prostate cancer study while securing fast track designation.
Frequently asked questions
More from Australia
Red Metal JV starts 750m Sharon Dam hole
Banks call 4.85% rate peak despite Bullock’s inflation warning
Finbar buys A$7.5m Ascot site for A$166m project
Empire Resources starts 2,000m RC drilling at Yuinmery
Artemis begins 750m drill hole at Sharon Dam
Environmental Group lifts debt facilities to A$12.5m
